225Ac-FAP-2286 / Clovis, 3B Pharma - LARVOL DELTA

Efficacy of 177Lu-FAP-2286 and 225Ac-FAP-2286 in Treating Pancreatic Adenocarcinoma With Lymph Node Metastasis. (PubMed, Clin Nucl Med) - "Here is a case of a 37-year-old woman with poorly differentiated pancreatic adenocarcinoma with lymph node metastasis who received 1 cycle of gemcitabine plus nab-paclitaxel, but relapsed a year ago. After that, the patient received an additional 2 cycles of 225Ac-FAP-2286 treatment. A follow-up 68Ga-FAP-2286 PET/CT scan revealed complete metabolic response of the lesions, and no severe adverse reactions were reported."

Journal • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer

NorthStar Medical Radioisotopes Announces Supply Agreement with Clovis Oncology for Therapeutic Radioisotope Actinium-225 (Ac-225) (Businesswire) - "NorthStar Medical Radioisotopes...announced the signing of a long-term supply agreement with Clovis Oncology...for the therapeutic medical radioisotope, actinium-225 (Ac-225). Under terms of the agreement, NorthStar will provide Clovis with its environmentally preferred, high purity non-carrier-added (n.c.a.) Ac-225. Clovis plans to use NorthStar’s Ac-225 to radiolabel its lead peptide-targeted radionuclide therapeutic candidate currently in development, FAP-2286, which targets fibroblast activation protein (FAP), a promising theranostic target with expression across many tumor types."

Licensing / partnership • Oncology

Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286 (Businesswire) - "Clovis Oncology...announced the initiation of a development, manufacturing, and services agreement with Evergreen Theragnostics to develop actinium-225-labeled-FAP-2286 (225Ac-FAP-2286). Under the agreement, Clovis and Evergreen intend to develop radiolabeling chemistry and analytical methods for use in potential future pre-clinical and clinical studies...Under the terms of the agreement, Evergreen will develop 225Ac-FAP-2286 at its facility in Springfield, N.J. The facility was purpose-built to develop and manufacture a variety of therapeutic radiopharmaceuticals, including those based on alpha-emitting isotopes such as 225Ac, from early development to commercial scale manufacturing."

Licensing / partnership • Oncology • Solid Tumor